Last reviewed · How we verify
Adjunctive Zonisamide
Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition.
Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition. Used for Adjunctive therapy for partial seizures in epilepsy, Adjunctive therapy for generalized tonic-clonic seizures.
At a glance
| Generic name | Adjunctive Zonisamide |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Anticonvulsant / Antiepileptic drug |
| Target | Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide blocks voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing. It also inhibits carbonic anhydrase, which may contribute to its anticonvulsant effects. When used adjunctively, it enhances seizure control in combination with other antiepileptic drugs.
Approved indications
- Adjunctive therapy for partial seizures in epilepsy
- Adjunctive therapy for generalized tonic-clonic seizures
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia
- Headache
- Nausea
- Nephrolithiasis (kidney stones)
- Oligohydrosis (decreased sweating)
Key clinical trials
- A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
- Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy (NA)
- Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy (PHASE4)
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (PHASE3)
- Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures (PHASE3)
- A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study) (PHASE3)
- Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy (PHASE3)
- Open-label Adjunctive Zonisamide for Bipolar Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjunctive Zonisamide CI brief — competitive landscape report
- Adjunctive Zonisamide updates RSS · CI watch RSS
- Eisai Inc. portfolio CI